DALLAS / Feb 21, 2024 / Business Wire / Tenet Healthcare Corporation (NYSE: THC) is scheduled to present at the Barclays Global Healthcare Conference on Tuesday, March 12, 2024, beginning at 9:30 a.m. Eastern time.
A live webcast and audio archive of the event may be accessed through the investor relations section of Tenet’s website at www.tenethealth.com/investors. The replay will be available for 30 days.
About Tenet Healthcare
Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in Dallas. Our care delivery network includes United Surgical Partners International, the largest ambulatory platform in the country, which operates or has ownership interests in more than 480 ambulatory surgery centers and surgical hospitals. We also operate 58 acute care and specialty hospitals, approximately 160 other outpatient facilities, a network of leading employed physicians and a global business center in Manila, Philippines. Our Conifer Health Solutions subsidiary provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers, and other clients. Across the Tenet enterprise, we are united by our mission to deliver quality, compassionate care in the communities we serve. For more information, please visit www.tenethealth.com.
Last Trade: | US$171.47 |
Daily Change: | -0.37 -0.22 |
Daily Volume: | 512,033 |
Market Cap: | US$16.310B |
April 29, 2025 February 12, 2025 October 29, 2024 July 24, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load